Comparing measures of hematologic response after high-dose melphalan and stem cell transplantation in AL amyloidosis

Hematologic complete response (hemCR) in AL amyloidosis requires absence of monoclonal protein by immunofixation electrophoreses (IFE) and normal serum free light chain ratio (FLCR). Recent literature suggests that an involved free light chain (iFLC)

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Blood cancer journal (New York) 2020-09, Vol.10 (8), p.88-88, Article 88
Hauptverfasser:	Sarosiek, Shayna, Zheng, Luke, Sloan, J. Mark, Quillen, Karen, Brauneis, Dina, Sanchorawala, Vaishali
Format:	Artikel
Sprache:	eng
Schlagworte:	692/699/1541 692/699/1541/1990/804 Adult Aged Amyloidosis Antineoplastic Agents, Alkylating - administration & dosage Antineoplastic Agents, Alkylating - therapeutic use Biomedical and Life Sciences Biomedicine Cancer Research Female Hematology Humans Immunoglobulin Light Chains - blood Immunoglobulin Light-chain Amyloidosis - blood Immunoglobulin Light-chain Amyloidosis - therapy Male Melphalan - administration & dosage Melphalan - therapeutic use Middle Aged Oncology Stem Cell Transplantation Stem cells Survival Analysis Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Beschreibung
Zusammenfassung:	Hematologic complete response (hemCR) in AL amyloidosis requires absence of monoclonal protein by immunofixation electrophoreses (IFE) and normal serum free light chain ratio (FLCR). Recent literature suggests that an involved free light chain (iFLC)
ISSN:	2044-5385 2044-5385
DOI:	10.1038/s41408-020-00354-7